Global and United States Generic Injectables Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

Market Analysis and Insights: Global and United States Generic Injectables Market
This report focuses on global and United States Generic Injectables market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Generic Injectables market size is estimated to be worth US$ 31770 million in 2022 and is forecast to a readjusted size of US$ 39060 million by 2028 with a CAGR of 3.5% during the review period. Fully considering the economic change by this health crisis, by Type, Small Molecule accounting for % of the Generic Injectables global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Oncology was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

Global Generic Injectables Scope and Market Size
Generic Injectables market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Generic Injectables market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Generic Injectables market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Generic Injectables market is segmented into
    Small Molecule
    Large Molecule

Segment by Application, the Generic Injectables market is segmented into
    Oncology
    Anesthesia
    Anti-Infectives
    Parenteral Nutrition
    Cardiovascular Diseases

Regional and Country-level Analysis
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Generic Injectables Market Share Analysis
Generic Injectables market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Generic Injectables business, the date to enter into the Generic Injectables market, Revenue in Generic Injectables Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Hospira (Pfizer Inc.)
    Fresenius Kabi
    Sandoz (Novartis)
    Hikma Pharmaceuticals PLC
    Dr. Reddy’s Laboratories Ltd
    Grifols
    Nichi-Iko Group (Sagent)
    Teva Pharmaceutical
    Auromedics
    Sanofi
    Gland Pharma
    Endo International PLC

 1 Study Coverage
    1.1 Generic Injectables Revenue in Generic Injectables Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Generic Injectables Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Generic Injectables Market Size for the Year 2017-2028
        1.2.2 Global Generic Injectables Market Size for the Year 2017-2028
    1.3 Generic Injectables Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Generic Injectables in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Generic Injectables Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Generic Injectables Market Dynamics
        1.4.1 Generic Injectables Industry Trends
        1.4.2 Generic Injectables Market Drivers
        1.4.3 Generic Injectables Market Challenges
        1.4.4 Generic Injectables Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Generic Injectables by Type
    2.1 Generic Injectables Market Segment by Type
        2.1.1 Small Molecule
        2.1.2 Large Molecule
    2.2 Global Generic Injectables Market Size by Type (2017, 2022 & 2028)
    2.3 Global Generic Injectables Market Size by Type (2017-2028)
    2.4 United States Generic Injectables Market Size by Type (2017, 2022 & 2028)
    2.5 United States Generic Injectables Market Size by Type (2017-2028)

 3 Generic Injectables by Application
    3.1 Generic Injectables Market Segment by Application
        3.1.1 Oncology
        3.1.2 Anesthesia
        3.1.3 Anti-Infectives
        3.1.4 Parenteral Nutrition
        3.1.5 Cardiovascular Diseases
    3.2 Global Generic Injectables Market Size by Application (2017, 2022 & 2028)
    3.3 Global Generic Injectables Market Size by Application (2017-2028)
    3.4 United States Generic Injectables Market Size by Application (2017, 2022 & 2028)
    3.5 United States Generic Injectables Market Size by Application (2017-2028)

 4 Global Generic Injectables Competitor Landscape by Company
    4.1 Global Generic Injectables Market Size by Company
        4.1.1 Top Global Generic Injectables Companies Ranked by Revenue (2021)
        4.1.2 Global Generic Injectables Revenue by Player (2017-2022)
    4.2 Global Generic Injectables Concentration Ratio (CR)
        4.2.1 Generic Injectables Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Generic Injectables in 2021
        4.2.3 Global Generic Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Generic Injectables Headquarters, Revenue in Generic Injectables Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Generic Injectables Headquarters and Area Served
        4.3.2 Global Generic Injectables Companies Revenue in Generic Injectables Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Generic Injectables Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Generic Injectables Market Size by Company
        4.5.1 Top Generic Injectables Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Generic Injectables Revenue by Players (2020, 2021 & 2022)

 5 Global Generic Injectables Market Size by Region
    5.1 Global Generic Injectables Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Generic Injectables Market Size by Region (2017-2028)
        5.2.1 Global Generic Injectables Market Size by Region: 2017-2022
        5.2.2 Global Generic Injectables Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Generic Injectables Market Size YoY Growth 2017-2028
        6.1.2 North America Generic Injectables Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Generic Injectables Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Generic Injectables Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Generic Injectables Market Size YoY Growth 2017-2028
        6.3.2 Europe Generic Injectables Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Generic Injectables Market Size YoY Growth 2017-2028
        6.4.2 Latin America Generic Injectables Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Generic Injectables Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Generic Injectables Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Hospira (Pfizer Inc.)
        7.1.1 Hospira (Pfizer Inc.) Company Details
        7.1.2 Hospira (Pfizer Inc.) Business Overview
        7.1.3 Hospira (Pfizer Inc.) Generic Injectables Introduction
        7.1.4 Hospira (Pfizer Inc.) Revenue in Generic Injectables Business (2017-2022)
        7.1.5 Hospira (Pfizer Inc.) Recent Development
    7.2 Fresenius Kabi
        7.2.1 Fresenius Kabi Company Details
        7.2.2 Fresenius Kabi Business Overview
        7.2.3 Fresenius Kabi Generic Injectables Introduction
        7.2.4 Fresenius Kabi Revenue in Generic Injectables Business (2017-2022)
        7.2.5 Fresenius Kabi Recent Development
    7.3 Sandoz (Novartis)
        7.3.1 Sandoz (Novartis) Company Details
        7.3.2 Sandoz (Novartis) Business Overview
        7.3.3 Sandoz (Novartis) Generic Injectables Introduction
        7.3.4 Sandoz (Novartis) Revenue in Generic Injectables Business (2017-2022)
        7.3.5 Sandoz (Novartis) Recent Development
    7.4 Hikma Pharmaceuticals PLC
        7.4.1 Hikma Pharmaceuticals PLC Company Details
        7.4.2 Hikma Pharmaceuticals PLC Business Overview
        7.4.3 Hikma Pharmaceuticals PLC Generic Injectables Introduction
        7.4.4 Hikma Pharmaceuticals PLC Revenue in Generic Injectables Business (2017-2022)
        7.4.5 Hikma Pharmaceuticals PLC Recent Development
    7.5 Dr. Reddy’s Laboratories Ltd
        7.5.1 Dr. Reddy’s Laboratories Ltd Company Details
        7.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
        7.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Introduction
        7.5.4 Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectables Business (2017-2022)
        7.5.5 Dr. Reddy’s Laboratories Ltd Recent Development
    7.6 Grifols
        7.6.1 Grifols Company Details
        7.6.2 Grifols Business Overview
        7.6.3 Grifols Generic Injectables Introduction
        7.6.4 Grifols Revenue in Generic Injectables Business (2017-2022)
        7.6.5 Grifols Recent Development
    7.7 Nichi-Iko Group (Sagent)
        7.7.1 Nichi-Iko Group (Sagent) Company Details
        7.7.2 Nichi-Iko Group (Sagent) Business Overview
        7.7.3 Nichi-Iko Group (Sagent) Generic Injectables Introduction
        7.7.4 Nichi-Iko Group (Sagent) Revenue in Generic Injectables Business (2017-2022)
        7.7.5 Nichi-Iko Group (Sagent) Recent Development
    7.8 Teva Pharmaceutical
        7.8.1 Teva Pharmaceutical Company Details
        7.8.2 Teva Pharmaceutical Business Overview
        7.8.3 Teva Pharmaceutical Generic Injectables Introduction
        7.8.4 Teva Pharmaceutical Revenue in Generic Injectables Business (2017-2022)
        7.8.5 Teva Pharmaceutical Recent Development
    7.9 Auromedics
        7.9.1 Auromedics Company Details
        7.9.2 Auromedics Business Overview
        7.9.3 Auromedics Generic Injectables Introduction
        7.9.4 Auromedics Revenue in Generic Injectables Business (2017-2022)
        7.9.5 Auromedics Recent Development
    7.10 Sanofi
        7.10.1 Sanofi Company Details
        7.10.2 Sanofi Business Overview
        7.10.3 Sanofi Generic Injectables Introduction
        7.10.4 Sanofi Revenue in Generic Injectables Business (2017-2022)
        7.10.5 Sanofi Recent Development
    7.11 Gland Pharma
        7.11.1 Gland Pharma Company Details
        7.11.2 Gland Pharma Business Overview
        7.11.3 Gland Pharma Generic Injectables Introduction
        7.11.4 Gland Pharma Revenue in Generic Injectables Business (2017-2022)
        7.11.5 Gland Pharma Recent Development
    7.12 Endo International PLC
        7.12.1 Endo International PLC Company Details
        7.12.2 Endo International PLC Business Overview
        7.12.3 Endo International PLC Generic Injectables Introduction
        7.12.4 Endo International PLC Revenue in Generic Injectables Business (2017-2022)
        7.12.5 Endo International PLC Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Generic Injectables Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Generic Injectables Market Trends
    Table 3. Generic Injectables Market Drivers
    Table 4. Generic Injectables Market Challenges
    Table 5. Generic Injectables Market Restraints
    Table 6. Global Generic Injectables Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Generic Injectables Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Generic Injectables Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Generic Injectables Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Generic Injectables Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Generic Injectables Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Generic Injectables Revenue Share by Player, 2017-2022
    Table 13. Global Generic Injectables Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Generic Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Injectables as of 2021)
    Table 15. Top Players of Generic Injectables in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Generic Injectables Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Generic Injectables Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Generic Injectables Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Generic Injectables Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Generic Injectables Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Generic Injectables Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Generic Injectables Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Generic Injectables Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Generic Injectables Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Generic Injectables Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Generic Injectables Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Generic Injectables Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Generic Injectables Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Hospira (Pfizer Inc.) Company Details
    Table 31. Hospira (Pfizer Inc.) Business Overview
    Table 32. Hospira (Pfizer Inc.) Generic Injectables Product
    Table 33. Hospira (Pfizer Inc.) Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 34. Hospira (Pfizer Inc.) Recent Development
    Table 35. Fresenius Kabi Company Details
    Table 36. Fresenius Kabi Business Overview
    Table 37. Fresenius Kabi Generic Injectables Product
    Table 38. Fresenius Kabi Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 39. Fresenius Kabi Recent Development
    Table 40. Sandoz (Novartis) Company Details
    Table 41. Sandoz (Novartis) Business Overview
    Table 42. Sandoz (Novartis) Generic Injectables Product
    Table 43. Sandoz (Novartis) Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 44. Sandoz (Novartis) Recent Development
    Table 45. Hikma Pharmaceuticals PLC Company Details
    Table 46. Hikma Pharmaceuticals PLC Business Overview
    Table 47. Hikma Pharmaceuticals PLC Generic Injectables Product
    Table 48. Hikma Pharmaceuticals PLC Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 49. Hikma Pharmaceuticals PLC Recent Development
    Table 50. Dr. Reddy’s Laboratories Ltd Company Details
    Table 51. Dr. Reddy’s Laboratories Ltd Business Overview
    Table 52. Dr. Reddy’s Laboratories Ltd Generic Injectables Product
    Table 53. Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 54. Dr. Reddy’s Laboratories Ltd Recent Development
    Table 55. Grifols Company Details
    Table 56. Grifols Business Overview
    Table 57. Grifols Generic Injectables Product
    Table 58. Grifols Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 59. Grifols Recent Development
    Table 60. Nichi-Iko Group (Sagent) Company Details
    Table 61. Nichi-Iko Group (Sagent) Business Overview
    Table 62. Nichi-Iko Group (Sagent) Generic Injectables Product
    Table 63. Nichi-Iko Group (Sagent) Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 64. Nichi-Iko Group (Sagent) Recent Development
    Table 65. Teva Pharmaceutical Company Details
    Table 66. Teva Pharmaceutical Business Overview
    Table 67. Teva Pharmaceutical Generic Injectables Product
    Table 68. Teva Pharmaceutical Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 69. Teva Pharmaceutical Recent Development
    Table 70. Auromedics Company Details
    Table 71. Auromedics Business Overview
    Table 72. Auromedics Generic Injectables Product
    Table 73. Auromedics Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 74. Auromedics Recent Development
    Table 75. Sanofi Company Details
    Table 76. Sanofi Business Overview
    Table 77. Sanofi Generic Injectables Product
    Table 78. Sanofi Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 79. Sanofi Recent Development
    Table 80. Gland Pharma Company Details
    Table 81. Gland Pharma Business Overview
    Table 82. Gland Pharma Generic Injectables Product
    Table 83. Gland Pharma Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 84. Gland Pharma Recent Development
    Table 85. Endo International PLC Company Details
    Table 86. Endo International PLC Business Overview
    Table 87. Endo International PLC Generic Injectables Product
    Table 88. Endo International PLC Revenue in Generic Injectables Business (2017-2022) & (US$ Million)
    Table 89. Endo International PLC Recent Development
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
List of Figures
    Figure 1. Generic Injectables Product Picture
    Figure 2. Global Generic Injectables Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Generic Injectables Market Size 2017-2028 (US$ Million)
    Figure 4. United States Generic Injectables Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Generic Injectables Market Size 2017-2028 (US$ Million)
    Figure 6. United States Generic Injectables Market Share in Global 2017-2028
    Figure 7. Generic Injectables Report Years Considered
    Figure 8. Product Picture of Small Molecule
    Figure 9. Product Picture of Large Molecule
    Figure 10. Global Generic Injectables Market Share by Type in 2022 & 2028
    Figure 11. Global Generic Injectables Market Size by Type (2017-2028) & (US$ Million)
    Figure 12. Global Generic Injectables Market Share by Type (2017-2028)
    Figure 13. United States Generic Injectables Market Share by Type in 2022 & 2028
    Figure 14. United States Generic Injectables Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. United States Generic Injectables Market Share by Type (2017-2028)
    Figure 16. Product Picture of Oncology
    Figure 17. Product Picture of Anesthesia
    Figure 18. Product Picture of Anti-Infectives
    Figure 19. Product Picture of Parenteral Nutrition
    Figure 20. Product Picture of Cardiovascular Diseases
    Figure 21. Global Generic Injectables Market Share by Application in 2022 & 2028
    Figure 22. Global Generic Injectables Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. Global Generic Injectables Market Share by Application (2017-2028)
    Figure 24. United States Generic Injectables Market Share by Application in 2022 & 2028
    Figure 25. United States Generic Injectables Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. United States Generic Injectables Market Share by Application (2017-2028)
    Figure 27. North America Generic Injectables Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. U.S. Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Canada Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Europe Generic Injectables Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. Germany Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. France Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. U.K. Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Italy Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Russia Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Generic Injectables Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 37. China Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Japan Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. South Korea Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. India Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Australia Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Taiwan Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Indonesia Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Thailand Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Malaysia Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America Generic Injectables Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Generic Injectables Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Turkey Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. UAE Generic Injectables Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Hospira (Pfizer Inc.) Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 55. Fresenius Kabi Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 56. Sandoz (Novartis) Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 57. Hikma Pharmaceuticals PLC Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 58. Dr. Reddy’s Laboratories Ltd Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 59. Grifols Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 60. Nichi-Iko Group (Sagent) Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 61. Teva Pharmaceutical Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 62. Auromedics Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 63. Sanofi Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 64. Gland Pharma Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 65. Endo International PLC Revenue Growth Rate in Generic Injectables Business (2017-2022)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

Market Analysis and Insights: Global and United States Generic Injectables Market
This report focuses on global and United States Generic Injectables market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Generic Injectables market size is estimated to be worth US$ 31770 million in 2022 and is forecast to a readjusted size of US$ 39060 million by 2028 with a CAGR of 3.5% during the review period. Fully considering the economic change by this health crisis, by Type, Small Molecule accounting for % of the Generic Injectables global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Oncology was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

Global Generic Injectables Scope and Market Size
Generic Injectables market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Generic Injectables market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Generic Injectables market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Generic Injectables market is segmented into
    Small Molecule
    Large Molecule

Segment by Application, the Generic Injectables market is segmented into
    Oncology
    Anesthesia
    Anti-Infectives
    Parenteral Nutrition
    Cardiovascular Diseases

Regional and Country-level Analysis
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Generic Injectables Market Share Analysis
Generic Injectables market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Generic Injectables business, the date to enter into the Generic Injectables market, Revenue in Generic Injectables Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Hospira (Pfizer Inc.)
    Fresenius Kabi
    Sandoz (Novartis)
    Hikma Pharmaceuticals PLC
    Dr. Reddy’s Laboratories Ltd
    Grifols
    Nichi-Iko Group (Sagent)
    Teva Pharmaceutical
    Auromedics
    Sanofi
    Gland Pharma
    Endo International PLC